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ABSTRACT  
31P-NMR and ESI-MS on the melanoma cytotoxic chlorotriphenylphosphine-1,3-
bis(diphenylphosphino)propanegold(I), [Au(DPPP)(PPh3)Cl], show partial decomposition that includes 
the novel dinuclear cation [Au2(DPPP)2Cl]+; its  structure was calculated using DFT. Unexpectedly, 
using the diphosphine ligand 1,2-bis(diphenylphosphino)ethane (DIPHOS), [{AuCl(PPh3)}2(µ2-
DIPHOS)] was obtained. Its X-ray crystal structure shows a unique triangular coordination sphere in 
contrast to T-shaped geometry of related gold(I)-DIPHOS compounds. Its cytotoxic activity in JR8, SK-
Mel-5 and 2/60 melanoma cell lines is dose-dependent and lower than [Au(DPPP)(PPh3)Cl] due to its 
non-chelating nature. An in vitro study of both gold compounds on the B16V melanoma cell line gives 
credence to this structure-activity relationship. IC50 indicate that both gold species are 10 times more 
active in B16V than in JR8, SK-Mel-5 and 2/60. Oxidation of [Au(DPPP)(PPh3)Cl] towards Au(III) 
compounds and phosphine-oxides is observed upon reaction with hypochlorite in water/DMSO solution, 
mimicking endogenous hypochlorite. A related reaction involving the formation of [AuCl4]- is 
thermodynamically feasible according to DFT calculations.  
 
KEYWORDS  
 
Melanoma, gold, phosphine, crystal structure, ESI-MS, DFT  
 
INTRODUCTION 
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There is much interest in the research of metal complexes as potential anticancer agents. Clinical 
use of cisplatin has induced the ongoing investigation of alternative metal-based anticancer agents, 
in the hope that metal centers other than platinum might produce specific and/or improved in vitro 
and in vivo anticancer effects and be developed as useful drugs.1-2 The clinically established 
antiarthritic gold(I) species auranofin, (1-thio-beta-D-glucopyranosato)(triethylphosphine)gold 
2,3,4,6-tetraacetate), and some other gold-phosphine compounds show significant antitumor 
properties, both in vitro and in vivo.3-4 Gold(I) complexes containing diphosphine ligands show 
greatest antitumor activity in vitro and in vivo in P388 and L1210 leukemias, M5076 reticulum 
cell sarcoma, B16 melanoma and Lewis lung carcinoma.5-8 
The site where gold(I)-monophosphine and -diphosphine complexes act is in mitochondria. 
Here, they cause uncoupling of oxidative phosphorylation alterating the inner mitochondrial 
membrane permeability to cations and protons with the consequent collapse of mitochondrial 
membrane potential (Tmt).9-13 The antitumor activity may be due to loss of Tmt, which results 
in decreased ATP synthesis and release of apoptogenic factors from the mitochondria into the 
cytosol,  leading to cell death.14-15 Considerable interest in the design and development of drugs 
that specifically compromise the structural and functional integrity of mitochondria is growing.16-
18 
With the aim to potentially increase antitumor activity through synergistic effects, the gold(I) 
complex [Au(DPPP)(PPh3)Cl], containing both mono- and di-phosphine ligands, was recently 
synthesized. It showed appreciable in vitro antiproliferative activity against the National Cancer 
Institute (NCI) 60-cell-line panel derived from tumors of different histotypes; melanoma was the 
most sensitive subgroup analyzed19 and thus we focus on this tumor type. Such selectivity has 
been recently confirmed on additional human melanoma cell lines (JR8, SK-Mel-5, Mel-501, 
2/60, 2/21 and GRIG) and the cytotoxic activity resulted higher than or comparable to that of 
cisplatin.20Additionally, apoptotic response of  JR8 and 2/60 cells exposed to 
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[Au(DPPP)(PPh3)Cl] showed a dose-dependent loss of mitochondrial membrane potential, release 
of cytochrome c and Smac/DIABLO from the mitochondria into the cytosol and a dose-dependent 
increase in apoptotic cells.20 Activity of gold complexes with chelating ligands PPh2(CH2)nPPh2 is 
higher for n = 2, 3  and therefore we attempted to synthesize the analogous mixed phosphine 
compound [Au(DIPHOS)(PPh3)Cl], i.e. a complex containing a -[(CH)2]2- link instead of -
[(CH)2]3- between the 2 PPh2 units, to test its influence on biological activity. We obtained an 
unexpected gold-DIPHOS species and below we describe the antiproliferative effect of this novel 
compound on 3 human melanoma cell lines, JR8, SK-Mel-5 and 2/60. We also include additional 
studies in solution using NMR and ESI-MS spectroscopy and outline differences between 
[Au(DPPP)(PPh)3Cl] and the gold-DIPHOS complexes, including the novel gold species 
[Au2(DPPP)2Cl]+, studied with DFT. An additional in vitro study was performed for both metal 
compounds on a murine melanoma in vitro cell line (B16V) derived from the in vivo transplanted 
B16 melanoma. 
RESULTS 
Diffraction Study of [{AuCl(PPh3)}2(µ2-DIPHOS)]. 
The X-ray crystal structure of [{PPh3AuCl}2(µ2-DIPHOS)] is depicted in Figure 1 and shows a non-
chelating DIPHOS ligand bridging 2 gold centers. A solvent chloroform molecule is included in the 
lattice and does not show chemical interactions with [{AuCl(PPh3)}2(µ2-DIPHOS)]. Therefore, the gold 
center is 3-coordinate, i.e., bound to one Cl and 2 P atoms, one from PPh3 and one from DIPHOS, and 
its coordination polyhedron is triangular. Table 1 lists selected structural features both for X-ray and 
DFT methods, which are described later. 
A literature search for Au-DIPHOS chelate, with 3-coordinate metal, shows only 3 compounds in the 
Cambridge crystallographic database, whereas for DIPHOS bridged gold species, with at least one gold 
atom 3-coordinate, there are 13 crystal structures. Therefore, having a non-chelate 3-coordinate gold(I)-
DIPHOS compound appears statistically favored. Most of these molecules have ring-like connectivity 
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and the gold coordination geometry is T-shaped, although sometimes ring constraints induce distortions; 
all have less triangular character than [{AuCl(PPh3)}2(µ2-DIPHOS)].  Nine out of the 13 compounds 
show interactions between both gold atoms as well. The most direct comparison is made with the only 
Cl derivative, µ2-2,3-bis(diphenylphosphino)-1,3-butadiene-P,P')-dichloro-digold(I),21 which has T-
shaped gold geometry with Au-Cl bond length of 2.30 Å and 2 Au-P about 2.24 Å. The gold 
coordination sphere of [{AuCl(PPh3)}2(µ2-DIPHOS)], besides differing because it is triangular, has 
weaker Au-P bonds (2.313(4) Å to PPh3 and 2.323(4) Å to DIPHOS). This suggests a poor gold 
protecting capacity by DIPHOS in [{AuCl(PPh3)}2(µ2-DIPHOS)], which is confirmed because most Au-
P(DIPHOS) bond lengths in the 13 structures mentioned above are generally much shorter, see Figure 2.  
Chemistry 
Crystalline [{AuCl(PPh3)}2(µ2-DIPHOS)] was obtained by mixing in 1:1 molar ratio chloroform 
solutions of chlorotriphenylphosphinegold(I), [Au(PPh3)Cl], and DIPHOS. In contrast, an equivalent 
process using DPPP in dichloromethane instead of DIPHOS, yielded [Au(DPPP)(PPh3)Cl] as previously 
described.19 [{AuCl(PPh3)}2(µ2-DIPHOS)] is air- and moisture-stable and has been fully characterized 
by spectroscopic methods (IR, NMR and ESI MS). Its IR spectrum shows the bands due to the 
phosphine ligands to be close to those of analogous phosphine gold(I) complexes.22-23A weak band at ca. 
320 cm-1 likely corresponds to (Au-Cl) vibration.23-25 Its 31P{1H} NMR spectrum, recorded at room 
temperature in CDCl3, shows three signals that can be assigned to different phosphorus environments. In 
the ESI-MS spectrum signals are associated with ionic species and it is only with this technique that we 
could observe the formation of a species, [Au(DIPHOS)(PPh3)]+, closely related to the one originally 
wanted. The reaction between [Au(PPh3)Cl] and DIPHOS in acetonitrile was monitored  with the same 
technique: When excess DIPHOS was employed, [Au(DIPHOS)2]+ was the only cation detected in 
solution; when using equimolar quantities two cations, [Au(PPh3)2]+ and [Au(DIPHOS)2]+, were found 
to coexist and with an excess of [Au(PPh3)Cl], the signals due to [(PPh3)(DIPHOS)Au]+,
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[(PPh3)(DIPHOS)Au2Cl]+ and [(PPh3)2(DIPHOS)Au2Cl]+ appeared, the latter increasing with the 
increase in [Au(PPh3)Cl] concentration. 
The 31P{1H} NMR spectrum of [Au(DPPP)(PPh3)Cl], in CDCl3 and DMSO, showed the existence of 
the following products: [Au(DPPP)(PPh3)Cl], [Au(DPPP)2]Cl, PPh3, [Au(PPh3)2Cl], whereas ESI-MS 
spectroscopy in MeCN indicated these cations: [Au(DPPP)PPh3]+, [Au(DPPP)2]+, [Au(PPh3)2]+ and 
[Au2(DPPP)2]Cl+, all of them known except the last one. Therefore, results of ESI-MS and NMR spectra 
demonstrate that [Au(DPPP)(PPh3)Cl] undergoes partial dissociation in CHCl3, DMSO and acetonitrile 
to give stable and known species, many of them carrying DPPP, and the novel cationic species  
[Au2(DPPP)2]Cl+, described later with DFT methods, see Scheme 2. 
Since recent studies showed that endogenous hypochlorite interacts with gold(I) anti-arthritic 
drugs26  we analyzed the hypochlorite oxidation of [Au(DPPP)(PPh)3Cl] to  Au(III) and found 
formation of several Au(III) species. First, we analyzed [Au(DPPP)(PPh3)Cl] by 1H and 
31P{1H}NMR in water/DMSO solution buffered at physiological pH. Its dissociation toward 
[Au(DPPP)2]Cl and [Au(PPh3)2Cl] depends on dilution and temperature. Signals due to 
[Au(DPPP)(PPh3)Cl], [Au(DPPP)2]Cl and [Au(PPh3)2Cl] are always present. When NaOD was 
added to the mixture, signals due to PPh3O and DPPPO2 were immediately observed. On the other 
hand 31P NMR spectra (CDCl3) of equimolar [Au(DPPP)(PPh3)Cl] and DCl indicate that 
[Au(DPPP)(PPh3)Cl] persists at low pH values, and the equilibrium shown in Scheme 3 is shifted 
to the right. 
When ClO- was added to a NMR test-tube containing a CDCl3 solution of [Au(DPPP)(PPh3)Cl], 
several signals appeared immediately. Some were assigned to the following species: 
[PPh3AuCl3],27 [(DPPP)AuCl2]Cl, [(PPh3)AuCl], [(DPPP)AuCl], [Au(DPPP)2]Cl. It is worth 
noting that upon ClO- addition the solution becomes yellow and [AuCl4]- was identified by UV 
spectroscopy.28 
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Acetonitrile/H2O solutions of [Au(DPPP)(PPh3)Cl] and ClO- have been also investigated by ESI MS 
spectroscopy. [AuCl4]- and [AuCl2]- in 5:1 ratio have been identified in the negative spectrum, whereas 
in the positive one, signals due to [(PPh3O)2 + Na]+, [(DPPPO2)2 + Na]+, [(PPh3O)(DPPPO2) + Na]+
[PPh3AuCl2]+, [(DPPP)AuCl2]+, [(PPh3)2Au]+, [(DPPP)(PPh3)Au]+ and [(DPPP)Au(Cl)(H2O)]++ are 
present depending on dilution of solution. Upon further addition of ClO-, the signals due to 
[(PPh3)2Au]+, [(DPPP)(PPh3)Au]+ disappear, whereas those due to [(PPh3O)2 + Na]+, [(DPPPO2)2 +
Na]+, [PPh3AuCl2]+, and [(DPPP)AuCl2]+ increase in intensity. When large excess ClO- is added, signals 
due to [PPh3AuCl2]+ and [(DPPP)AuCl2]+ also disappear and the only one present for gold containing 
species is due to [AuCl4]-. By adding PPh3 or DPPP to this solution, [PPh3AuCl2]+, and [(DPPP)AuCl2]+
form again. Finally addition of strong excess of PPh3 regenerates PPh3AuCl, as expected.28 
Spectroscopic data therefore suggest that reacting [Au(DPPP)(PPh3)Cl] with ClO- oxidizes gold(I) to 
gold(III), as confirmed by the presence of several gold(III)-phosphine cations and [AuCl4]- in the ESI 
MS spectrum. This is also supported by the fact that addition of an equimolar quantity of PPh3 to the 
above NMR solution produces PPh3AuCl3. The oxidation of gold(I) to gold(III) is accompanied by the 
oxidation of both phosphine donors to phosphinooxide species. 
In conclusion, 31P NMR spectra of chloroform (or D2O/DMSO) solutions containing 
[Au(DPPP)(PPh3)Cl] and ClO- agree with ESI MS spectra of acetonitrile solution containing the same 
species; these are input for DFT calculations also described later.  
Cytotoxic activity 
The in vitro cytotoxic activity of the gold complex [{AuCl(PPh3)}2(µ2-DIPHOS)] was 
investigated in JR8, SK-Mel-5 and 2/60 human melanoma cell lines exposed to different 
concentrations (from 0.1 to 1000 µM) for 48 h. A dose-dependent inhibition of cell growth was 
observed in all cell lines (Figure 3), with IC50 values ranging from 2.7 to 28 µM. This cytotoxic 
effect was compared to that reported for [Au(DPPP)(PPh3)Cl],20 under the same experimental 
conditions (Table 2):  the DIPHOS complex was less potent than the DPPP one in inhibiting cell 
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growth. A related study was performed on the B16V murine melanoma cell line for both 
[Au(DPPP)(PPh3)Cl] and [{AuCl(PPh3)}2(µ2-DIPHOS)]. The dose-response curves obtained for 
the two compounds are depicted in Figure 4; non linear regression analysis gave IC50 values of 
0.09 ± 0.02 µM and 0.32 ± 0.08 µM, respectively (mean ± SD of 4 independent experiments). The 
difference between the two values is highly statistically significant by Student’s t test for 
independent samples (p < 0.001).   
Theoretical calculations 
The structural features of [Au2(DPPP)2Cl]+ were investigated with DFT. Initial coordinates for a non-
chelate arrangement (Scheme 4, left) were obtained after modification of the closely related bis([2-
chloro)-bis([2-R,S-(1-diphenylphosphinobut-2-yl)-diphenylphosphinite)-di-gold(I) crystal structure,29 
see Figure 5. In addition, an alternative connectivity having two chelating “Au(DPPP)” moieties linked 
by the bridging Cl atom was explored (Scheme 4, right). The molecule having the lowest energy showed 
a Au-Cl-Au moiety typical of aurophilic interaction and is shown in Figure 6. [{PPh2AuCl}2(µ2-
DIPHOS)] was investigated with DFT technique because anisotropic crystalline decay was seen during 
data collection. Initial coordinates from the X-ray structure were geometry minimized and the triangular 
coordination resulted more regular.  
To study the reactivity of ClO- towards [Au(DPPP)(PPh3)Cl] we decreased calculation time by replacing 
all Ph groups with methyls in phosphine ligands so that [Au(DPPP)(PPh3)Cl] was modeled as 
[Au(DMPP)(PMet3)Cl]. When comparing the calculated structures of [Au(DMPP)(PMet3)Cl] and its 
cationic derivative [Au(DMPP)(PMet3)]+ it is seen that the role of Cl- is almost insignificant from a 
structural viewpoint, as the distance between the Au and the plane made by the 3 P atoms is 0.280 Å and  
0.016 Å, respectively: that is, both complexes can be considered as 3-coordinate. Since 
[Au(DPPP)(PPh3)]+ is observed experimentally with NMR and ESI-MS, and its solubility is higher than 
[Au(DPPP)(PPh)3Cl] in biological fluids, we suggest that this cationic species may be the active drug 
Page 8 of 32
ACS Paragon Plus Environment
Submitted to the Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review. Confidential - ACS
9
and so  we modeled the redox process using [Au(DMPP)(PMet3)]+ as starting material (see Scheme 5). 
G for this reaction is -126.7 kcal/mol and indicates thermodynamic feasibility. 
DISCUSSION 
Melanoma is the most aggressive of skin tumors, and disseminated disease is characterized by a very 
poor clinical outcome, not modified by conventional anticancer treatments.30 New agents and novel 
approaches are under preclinical evaluation for this malignancy.31 In this context, it has been shown that 
[Au(DPPP)(PPh3)Cl] is highly cytotoxic against several human tumor cell lines and displays a selective 
activity in melanoma cells.19 This activity has been recently confirmed on other human tumor cells, and 
demonstrated to be related to apoptosis induction associated with impairment of mitochondrial 
function.20 
The aim of the present study was to assess on the cytotoxicity the effect of shortening the bridge 
between PPh2 units, that is modifying -[(CH)2]3- to  -[(CH)2]2-. The rationale for this synthesis was also 
supported by the fact that less lipophilic phosphines are more tumor-selective and induce fewer side 
effects in their gold chelates.32 
Applying the same synthetic route19 used for [Au(DPPP)(PPh3)Cl] gave crystalline 
[{AuCl(PPh3)}2(µ2-DIPHOS)] as proven by diffraction methods; this compound was chemically 
characterized with IR, NMR, ESI-MS spectroscopy and elemental analyses. The X-ray crystal structure 
of [{AuCl(PPh3)}2(µ2-DIPHOS)] shows a non-chelating DIPHOS ligand as it links 2 gold centers. 
Therefore, the metal is 3-coordinate, i.e., bound to one Cl and 2 P atoms, one from PPh3 and one from 
DIPHOS. Considering that a) DIPHOS induces a lower bite angle than DPPP and b) the tendency of 
gold(I) to stabilize low coordination numbers (2 or 3 are more preferred than 4), we suggest that in 
combination the formation of a non chelating species is induced; this is statistically favored as seen in 
the literature (Figure 2).   
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In JR8, SK-MEL-5 and the melanoma clone 2/60 cell lines the in vitro cytotoxicity of 
[{AuCl(PPh3)}2(µ2-DIPHOS)] shows higher IC50 values (1.5 times or more) than those reported for 
[Au(DPPP)(PPh)3Cl].20 Therefore, we performed a comparative study in solution for both species to 
determine a possible explanation for the systematic difference in activity. Since [Au(DPPP)(PPh3)Cl] 
undergoes partial dissociation in solution to several compounds including the cytotoxic agent 
[Au(DPPP)2]+, the resulting variety may help increasing the possibility of transporting DPPP to the 
target, (scheme 2). One of these compounds is the novel cationic species [Au2(DPPP)2Cl]+, whose 
equivalent was not detected for [{AuCl(PPh3)}2(µ2-DIPHOS)]. Its structural features were investigated 
with DFT methods that gave the following observations: (1) a non chelating connectivity having a Cl-
bridged structure (Figure 5); (2) an alternative connectivity having two “Au(DPPP)2” chelate moieties 
bridged by the Cl atom, depicted in Figure 6, with an Au—Au separation of 2.711 Å thus showing a 
stronger aurophilic interaction compared to related crystalline compounds having the same Au-Cl-Au 
moiety. 
Therefore, by shortening the distance between both PPh2 groups (using DIPHOS instead of DPPP) a 
different gold complex is stabilized: having a unique triangular gold coordination and a non-chelating 
structure with weaker Au-P bonds than related non-chelate Au-DIPHOS compounds. Since a chelating 
ligand establishes stronger metal binding than a non-chelating one, the latter complex is less stable 
possibly explaining the lower activity than that observed for [Au(DPPP)(PPh3)Cl]. This structure-
activity relationship suggests a straightforward test on the crystal structures of other potential gold(I)-
diphosphines: a strong Au-P  binding favors diphosphine metal protection and increases access to the 
target. To check this hypothesis we performed additional tests for both gold compounds on the B16V 
murine melanoma cell line. From dose-response curves following 48h exposure to [Au(DPPP)(PPh3)Cl] 
and [{AuCl(PPh3)}2(µ2-DIPHOS)] IC50 values of 0.09 and 0.32 µM, respectively, were obtained. These 
results confirm that the non-chelate complex [{AuCl(PPh3)}2(µ2-DIPHOS)] has weaker activity than the 
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chelate complex  [Au(DPPP)(PPh3)Cl]. The activity of both complexes in the B16V panel is about 10 
times higher than in JR8, SK-MEL-5 and 2/60 cell lines.  
The mechanism of action of gold(I)-diphosphines derivatives is still largely unknown. Gold 
seems to function as a carrier for the diphosphine ligand which can be displaced, for example, by 
thiol groups reacting with gold(I). The resulting  free diphospines are able to function as 
antiproliferative agents.33-35 However, a more direct involvement of gold in antitumor activity is 
feasible, as some gold(III) compounds, without any phosphine bound to the metal, are also active 
against several tumor models.36 Potential explanations may come from clinically used anti-arthritic 
Au(I) drugs as they do not cause the release of peptide from human leukocyte antigen (HLA-DR1) 
in vitro but the Au(III) square-planar compound K[AuCl4] releases peptides from HLA-DR4,37 
which are frequently found in individuals with rheumatoid arthritis; these features were also 
analyzed for other isoelectronic square-planar complexes (cisplatin and K2[PdCl4]). Oxidation of 
Au(I) to Au(III) has been reported  in vivo38 and in vitro39 and Au(III) metabolites formed in vivo 
are responsible for severe allergic side effects from gold therapy. In addition, Au(I) 
pharmaceuticals are considered pro-drugs that convert to Au(III) after interaction with 
hypochlorite produced by phagocytes.26 Using spectroscopic NMR and ESI MS of solution 
chemistry we show that upon addition of hypochlorite to [Au(DPPP)(PPh3)Cl] there is oxidation 
to [AuCl4]-, DPPPO2 and PPh3O. A DFT investigation that includes structural calculations of 
these compounds finds a related oxidation reaction having thermodynamic feasibility. 
CONCLUSIONS 
The confirmation of chelating diphosphines as a necessary feature for effective antitumor activity 
in their gold(I) derivatives is shown by [Au(DPPP)(PPh3)Cl] being more effective than 
[{AuCl(PPh3)}2(µ2-DIPHOS)] against melanoma. [Au(DPPP)(PPh3)Cl] decomposition in solution 
includes the novel cation [Au2(DPPP)2Cl]+ whose biological role is not clear at present. In 
addition, redox interaction of [Au(DPPP)(PPh3)Cl] with the endogenous hypochlorite anion leads 
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to the corresponding square-planar [AuCl4]- and phosphine oxidation; DFT shows this reaction to 
be thermodynamically favorable and perhaps related to the antitumor mechanism of action.  
Experimental Section 
Chemistry 
DIPHOS, DPPP and (PPh3)AuCl were purchased from Aldrich and used without further purification. 
All solvents were dried, degassed, and distilled prior to use. Elemental analyses (C, H) were performed 
with a Fisons Instruments 1108 CHNS-O Elemental analyzer. Buffer solution (Fluka) pH 9.0 (20.0°C) 
Sodium tetraborate (borax/hydrochloricacid); pH 5.0 (20°C) sodium citrate. IR spectra were recorded 
from 4000 to 100 cm-1 with a Perkin-Elmer System 2000 FTIR instrument. 1H and 31P{1H} NMR 
spectra, referenced to Si(CH3)4 and external 85% H3PO4 respectively, were recorded on a VXR-300 
Varian spectrometer (300 MHz for 1H, and 121.4 MHz for 31P). Relative intensity of signals is given in 
square brackets and J in hertz. The interaction of [Au(DPPP)(PPh3)Cl] with hypochlorite was studied 
with 1H and 31PNMR spectra recorded on a Mercury Plus Varian 400 NMR spectrometer (400 MHz for 
1H, and 162.1 MHz for 31P). Positive and negative electrospray mass spectra were obtained with a Series 
1100 MSI detector HP spectrometer, using an acetonitrile mobile phase. Solutions (3 mg/mL) for 
electrospray ionization mass spectrometry (ESI-MS) were prepared using reagent grade acetonitrile. For 
the ESI-MS data, masses and intensities were compared to those calculated by using the IsoPro Isotopic 
Abundance Simulator, version 2.1;40 peaks containing chloride are identified as the centres of isotopic 
clusters. 
Chloro-triphenylphosphine-1,3-bis(diphenylphosphino)propane-gold(I), [Au(DPPP)(PPh3)Cl], 
was synthesized as previously reported.19 IR (Nujol mull, cm-1): 3060w, 3039w, 1990w, 1906w, 1826w, 
1770w, 1671w, 1582m, 1569m, 1436m, 1313m, 1196br, 1094s, 1070w, 1043w, 1026w, 998w, 971m, 
824m, 794m, 761m, 747m, 738m, 722m, 710m, 697s, 648m, 617w, 547m, 530m, 515s, 508s, 491m, 
470m, 429m, 398w, 357w, 329w, 302w, 280w, 252sh, 248w, 227w. 1H NMR (CDCl3, 295 K, 	 ppm): 
2.2 br (CH2, 2H), 2.6br (CH2, 4H), 7.0-7.7m br (CHPh, 35H). 31P NMR (DMSO, 293K, 	 ppm): 0.11br 
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[10], 26.6br [1], 31.0 [2], 31.7br [10], 34.62br [30]. 31P NMR (CDCl3, 293K, 	 ppm): -1.7br [1], 26.4br 
[1], 32.7br [1].  
The 31P{1H} NMR spectrum of [Au(DPPP)(PPh3)Cl], taken at room temperature in CDCl3, shows 3 
signals that can be assigned to the two different phosphorus environments in the complex (PPh3 and 
DPPP) and to [Au(DPPP)2]Cl. Some minor signals appear after 30 min due to free PPh3 and 
[Au(PPh3)2Cl], suggesting partial dissociation of the complex in this solvent. A similar behavior has 
been displayed in DMSO where the predominant species are [Au(DPPP)2]Cl, [Au(DPPP)PPh3Cl] and 
[Au(PPh3)2Cl] respectively. 
To confirm the dissociation equilibrium in solution of [Au(DPPP)(PPh3)Cl] an  electron spray 
ionization mass spectrometry (ESI-MS) study was carried out on its MeCN solutions  at different 
concentrations. In the positive mode the following cations were identified: [Au(DPPP)(PPh3)]+,
[Au(DPPP)2]+, [Au(PPh3)2]+ and [Au2(DPPP)2]Cl+, with the latter 3 species being less abundant.  
ESI-MS (MeCN): + 721.5 [10] [(PPh3)2AuCl]+, 871.7 [80] [Au(DPPP)(PPh3)]+ , 1021.8 [100] 
[Au(DPPP)2]+, 1253.8 [5] [Au2(DPPP)2]Cl]+. Therefore, by combining ESI-MS and NMR spectra it is 
demonstrated that this compound undergoes partial dissociation in CHCl3, DMSO and MeCN yielding 
stable and known species plus the novel cationic species  [Au2(DPPP)2]Cl+.
Interaction of [Au(DPPP)(PPh3)Cl] with hypochlorite. 31P NMR (CDCl3, 293K, 	 ppm): 16.5s 
[10], 27.8s [2], 28.2s [1], 29.2 [2], 30.6 [10], 33.5d [2] (82Hz), 34.1 [5], 34.2 [10], 41.1d [2] (44Hz), 
41.9 [2], 45.0 [2]. 1H NMR (CD2Cl2, 293K, 	 ppm): 1.9 br (2H, CH2DPPP), 1.9 br (2H, CH2DPPP), 2.7 br 
(4H, CH2DPPP), 7.0-8.0 (35H, CHPPh3 + DPPP)
ESI MS (MeCN, 25 °C): (–) 338.8 [100] (AuCl4-), 266.9 [40] (AuCl2-). (+) 911 [100] ((DPPPO2)2 +
Na+), 745 [40] [(PPh3O)(DPPPO2) + Na]+, 679 [65] [(DPPP)AuCl2]+ , 529 [25] [(PPh3)AuCl2]+, 445 
[80] [(DPPPO2) + H]+.
Bis(chloro-triphenylphosphinegold(I))-µ2-1,2-bis(diphenylphosphino)ethane. Since crystalline 
[Au(DPPP)(PPh3)Cl] was obtained from slow evaporation of [Au(PPh3)Cl] and DPPP in 
Page 13 of 32
ACS Paragon Plus Environment
Submitted to the Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review. Confidential - ACS
14
dichloromethane (1:1 ratio),19 we mixed [Au(PPh3)Cl] and DIPHOS accordingly. Crystalline material 
from chloroform solutions was obtained and, unexpectedly, diffraction methods showed it to be 
[{AuCl(PPh3)}2(µ2-DIPHOS)]. When trying the same 1:1 ratio in diethyl ether, [(DIPHOS)2Au]+
formed, that is a different product than obtained from chloroform. However, reacting [Au(PPh3)Cl] and 
DIPHOS (2:1) in diethyl ether yielded [{AuCl(PPh3)}2(µ2-DIPHOS)], as reported above for chloroform. 
That is, upon addition of 0.41 g of DIPHOS (ca 1.0 mmol) to a suspension (50 mL) of [Au(PPh3)Cl] 
(1.00 g, ca. 2.0 mmol) in diethyl ether, a colorless precipitate formed. The suspension was then stirred 
for 4 h and filtered and the precipitate washed with diethyl ether (20 mL) to give 0.70 g (0.5 mmol, 
50%) of the title compound, mp 189-191 °C. Anal. (C62H54Au2Cl2P4) C, H. IR (Nujol mull, cm-1): 
3050w, 3020w, 1585w, 1572w, 545m, 532m, 515s, 508s, 492s, 454m. 1H NMR (CDCl3): 	 2.5 (br, 2H, 
CH2), 3.0 (br, 2H, CH2), 7.2-7.8 (m, 50H, C6H5). 31P NMR (CDCl3): 21.14, 33.35, 34.55. ESI MS (+) 
(CH3CN): 721.5 (30) [(PPh3)2Au+], 857.5 (40) [(PPh3)(DIPHOS)Au+], 993.8 (100) [(DIPHOS)2Au+], 
1090 (20) [(PPh3)(DIPHOS)Au2Cl+], 1352 (10) [(PPh3)2(DIPHOS)Au2Cl+], 1457 (5) 
[(DIPHOS)2Au3Cl2+]. When different molar ratios were employed, for example Au(PPh3)Cl : DIPHOS 
(1:1) or Au(P(Ph3)Cl : DIPHOS (1:2), the well-known [Au (DIPHOS)2]Cl formed. 
X-ray Study of [{AuCl(PPh3)}2(µ2-DIPHOS)].
Very slow evaporation of this compound in chloroform solution afforded plate shaped crystals. A 
preliminary Weissenberg study showed cell parameters and space group. Crystal was placed in a quartz 
capillary to attenuate the strong and anisotropic decay. The molecular structure was determined with the 
Patterson function and successive Fourier localizations using CAOS program.41 The obtained high Rf is 
probably due to anisotropic crystal decay. The molecule is centro-symmetric with the inversion center 
located half way along the ethylene bridge. The asymmetric unit is half a molecule plus CHCl3 so that 
the crystalline compound is formally [{AuCl(PPh3)}2(µ2-DIPHOS)]  2 CHCl3. Table S4 shows 
crystallographic data. 
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Theoretical Study  
The structural features of the novel cationic species [Au2(DPPP)2Cl]+ were analyzed with density 
functional theory (DFT) using the Accelrys program Cerius2 4.6, subroutine DMol3 on an Octane SGI 
computer.42 Reliability of this program was already observed in performing structural calculations on 
related compounds.43 Due to the large scale calculations, an electron core potential (ECP) technique was 
employed. Local density was the Perdew and Wang (PWC) functional44 using a double numeric basis set 
with polarization functions (DNP)45 on all atoms. Initial coordinates for a non-chelate arrangement of 
[Au2(DPPP)2Cl]+ (Scheme 4, left) were obtained after modification of the closely related bis([2-
chloro)-bis([2-R,S-(1-diphenylphosphinobut-2-yl)-diphenylphosphinite)-di-gold(I) crystal structure,29 
which possesses 2 Cl atoms bridging the 2 metal centers,  and a C-C-O link between the 2 PPh2
moieties. Therefore, this link was updated to –(CH2)3–and one Cl atom was excluded. To ensure 
obtaining an absolute energy minimum, discrete modifications of the initial structure were performed; 
all of them converged to the same geometry, see Figure 5. The Au-Au separation of 4.441Å is slightly 
longer than the one from which the structure was modeled (4.338 Å). Cartesian coordinates of the 
converged structure are deposited in Supporting Information Available (Table S1). Gold(I) shows 
marked preference for coordination number 2 and an alternative configuration without the Cl bridge was 
also explored. In this arrangement one gold is 3-coordinate, bound to Cl and 2 P atoms, and the other 
gold is 2-coordinate, bound to 2 P atoms. Several models of this type did not reach convergence and 
their minimization paths became erratic. Also, resulting structures using these pathways showed energy 
markedly higher than the bridged structure and we conclude that the Au-Cl-Au bridged cation is 
preferred to the one having a terminal Cl. 
An alternative connectivity having two chelating “Au(DPPP)” moieties linked by a l atom was also 
explored (Scheme 4, right). The coordinates of the flexible tri-methylene bridge and the phenyls were 
widely varied to avoid trapping in non absolute minima. The best converged molecule possesses a Au-
Cl-Au moiety typical of aurophilic interaction and is shown in Figure 6; related coordinates are also 
Page 15 of 32
ACS Paragon Plus Environment
Submitted to the Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review. Confidential - ACS
16
deposited in Supporting Information Available (Table S2). The same DMol3 conditions were used to 
refine the molecular structure of the crystalline [{AuCl(PPh3)}2(µ2-DIPHOS)] species.  
Calculations for oxidation of [Au(DPPP)(PPh3)Cl] to [AuCl4]- , PPh3O and DPPPO2 were performed 
using DMol3 as implemented in the program Materials Studio 4.0 (PC version) using a BP/DNP basis 
set closely related to that used in the SGI platform, and including relativistic effects for the metal. 
Biological Study  
Cell lines 
Human melanoma cell lines, JR8, SK-MEL-5 and the melanoma clone 2/60 (selected from the human 
melanoma cell line 665/2 by micromanipulation in soft agar), were used to compare with related data.20 
The biological characteristics of JR8, SK-MEL-5, and 2/60 have been previously described.46-47 Cell 
lines were maintained in logarithmic growth phase at 37°C in a 5% CO2 humidified atmosphere in air. 
RPMI-1640 medium (Biowhittaker, Verviers  Industries, Kibbutz Beth Haemek, Israel), containing 10% 
fetal calf serum, 2 mM L-glutamine and 0.1 mg/ml gentamycin was used for all cell lines. For these cell 
lines the experiments were performed within 10 passages from thawing. An additional test in vitro was 
performed for both compounds in the B16V cell line. This murine model, an in vitro line derived from 
the in vivo transplanted B16 melanoma, was a gift from Dr. R. Supino (Istituto Nazionale Tumori, 
Milan, Italy).48 Cells were maintained in RPMI-1640 medium (Sigma-Aldrich, Milan, Italy), 
supplemented with 10% fetal bovine serum (Celbio, Italy), 2 mM glutamine, 1% antibiotic mixture and 
0.03 mM K3Fe(CN)6 at 37°C in a humidified 5% CO2 atmosphere.   
Drugs 
[{AuCl(PPh3)}2(µ2-DIPHOS)]  was reconstituted in sterile DMSO at a concentration of 5 mM 
and then diluted with sterile water to the desired concentrations, immediately before each 
experiment, for JR8, SK-MEL-5, the melanoma clone 2/60 and B16V cell lines. The same 
technique was applied for [Au(DPPP)(PPh3)Cl] in the B16V cell line. 
Cell survival assay 
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The sulforhodamine B (SRB) assay was performed on all the cell lines tested as described49 
with minor modifications. Briefly, according to the growth profiles previously defined for each 
cell line, adequate numbers of cells in 0.2 ml culture medium were plated in each well of a 96-well 
plate and allowed to attach for 24 h. Cells were exposed at 37°C for 48 h to different 
concentrations of the two gold complexes ranging between 0.1-1000 µM for the human melanoma 
cell lines or between 0.01-10 µM for B16V cells. Each experiment included eight replications for 
each concentration tested; control samples were run with 0.2% DMSO. At the end the 48 h period 
of incubation with the gold complexes, cells were fixed and processed for SRB staining. The 
optical density (OD) was read at 550 nm using a Universal Microplate Reader EL800 (Bio-Tek 
Instruments) and the results were expressed as cell growth obtained from the ratio of the 
absorbance values of gold complex-treated samples and those of controls. Dose-response curves 
were analyzed by nonlinear regression analysis and IC50 values were estimated using GraphPad 
Prism software, v. 4.03. The in vitro activity of the drugs was expressed as IC50 (i.e. the 
concentration inhibiting cell proliferation by 50%).  
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(Table S2) converged structures of [Au2(DPPP)2Cl]+, and for  [{AuCl(PPh3)}2(µ2-DIPHOS)] (Table 
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Table 1. Selected structural parameters of [{AuCl(PPh3)}2(µ2-DIPHOS)]. 
Method X-ray DFT 
Au - P(Ph) 2.313(4) 2.483 
Au -P(DIPHOS) 2.323(4) 2.485 
Au -Cl 2.632(5) 2.538 
P(DIPHOS) - Au - P(Ph) 145.2(2) 131.0 
Cl- Au - P(Ph) 108.9(2) 115.9 
Cl - Au - P(DIPHOS) 105.8(2) 113.0 
Table 2. Cytotoxic activity of gold complexes in human melanoma cell lines 
 
IC50 (µM) 
 ___________________________________________ 
 [{AuCl(PPh3)}2(µ2-DIPHOS)] [Au(DPPP)(PPh3)Cl] 
 ___________________________________________ 
 
JR8   28 ± 0.33 0.8 ± 0.11
SK-MEL-5  2.7 ± 0.11 1.0 ± 0.56
2/60   5.5 ± 0.085 1.7 ± 0.47
_______________________________________________________________________________ 
IC50 values were determined graphically from the growth inhibition curves obtained after a 48-h exposure of the cells 
to each drug. Data represent mean values ± SD of three independent experiments. Values for [Au(DPPP)(PPh3)Cl] are 
taken from the literature.20 
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Figure Captions 
Figure 1. X-ray crystal structure of [{AuCl(PPh3)}2(µ2-DIPHOS)] showing ellipsoid displacement 
parameters. For 2 Ph groups only the ipso carbons are shown and all H-atoms are omitted for clarity; P 
black, C grey, Au white, Cl light grey. The inversion center of this molecule is located in the ethylene 
bridge between C31 and C31’.  
Figure 2. Graph from 13 non-chelate gold(I)-DIPHOS crystal structures found at the CSD (listed in 
Supporting information available); some of these species have more than one independent molecular 
unit.   
Figure 3. Dose-response curves of human melanoma cell lines (JR8, k 2/60, l SK-MEL-5) 
exposed to [{AuCl(PPh3)}2(µ2-DIPHOS)] for 48 h. Points represent mean values ± SD of three 
independent experiments. 
Figure 4. Dose-response curves obtained from B16V cells exposed to [{AuCl(PPh3)}2(µ2-
DIPHOS)] (k) and [Au(DPPP)(PPh3)Cl] (•) for 48 h. Points represent the mean ± SD of four 
independent experiments. 
Figure 5. A non-chelate structure of [Au2(DPPP)2Cl]+ obtained with DFT methods and having 
aromatic H atoms omitted for clarity; P orange, C grey,  H white, Au purple, Cl green. 
Figure 6. The chelate structure of [Au2(DPPP)2Cl]+ obtained with DFT methods and having H atoms 
omitted for clarity ; P orange, C grey,  H white, Au purple, Cl green. 
Figure 7. Geometry optimized triangular [AuI(DMPP)(PMet3)]+ complex; P orange, C grey,  H 
white, Au purple. 
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Figure 6.  
 
Figure 7 
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Scheme 1: Diphosphine ligands used in this work. 
Scheme 2: Decomposition of [Au(DPPP)(PPh3)Cl]. 
[Au(DPPP)(PPh3)Cl]  [Au(DPPP)2]Cl + [Au(PPh3)2Cl] 
Scheme 3:       
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Scheme 4: Non-chelate and chelate connectivity of [Au2(DPPP)2Cl]+.
[AuI(DMPP)(PMet3)]+ + 2[H]+ + 4[OCl] -  [AuIIICl4]- + DMPPO2 + PMet3O + H2O
Scheme 5: A modeled hypochlorite oxidation for Au(I) to Au(III). 
 
TOC 
The naturally occurring endogenous hypochlorite anion may oxidize the melanoma antitumor 
compound  [AuI(DPPP)(PPh3)Cl] forming [AuIIICl4]- and phosphine oxides; DFT calculated 
DeltaG is -126.7 kcal/mol for a related model reaction. 
This non-chelate Au(I)-diphosphine  species [{AuCl(PPh3)}2(µ2-DIPHOS)] 
Cl

Ph
Ph
Au Au
C31
is slightly less active than the chelate [Au(DPPP)(PPh3)Cl] against several in vitro melanoma cell lines. 
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